Ehrlich and colleagues developed an immunotoxin named BW-2, consisting of an antibody against a RNA-binding protein in neurons called HuD and the toxin saporin, for the treatment of SCLC and neuroblastoma in HuD-expressing cancer cells and tumor models. Here, ELAVL4 is linked to neuroblastoma.